ArticleTranslational oncology2010

Three paths to better tyrosine kinase inhibition behind the blood-brain barrier in treating chronic myelogenous leukemia and glioblastoma with imatinib.

Richard E Kast et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.